Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 301–400 of 1,044
Genetics of Familial Hypercholesterolemia: New Insights
Vrablík, M., Tichý, L., Freiberger, T., Blaha, V., Satny, M., & Hubacek, J. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.574474 · Cited by 136
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Kasichayanula, S., Grover, A., Emery, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Gibbs, J. P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0620-7 · Cited by 135
Hopkins, P. N., Defesche, J., Fouchier, S. W., Bruckert, E., Luc, G., Cariou, B., Sjouke, B., Leren, T. P., Harada-Shiba, M., Mabuchi, H., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.115.001129 · Cited by 117
Self-citationMarduel, M., Ouguerram, K., Serre, V., Bonnefont-Rousselot, D., Marques-Pinheiro, A., Erik Berge, K., Devillers, M., Luc, G., Lecerf, J.-M., Tosolini, L., et al. (2013) · Human Mutation · doi:10.1002/humu.22215 · Cited by 133
“…associated with mutations in the wellknown LDLR (LDL receptor) (Familial Hypercholesterolemia (FH) MIM# 606945), APOB (apolipoprotein B-100) (Familial ligandDefective apolipoprotein B-100 (FDB) MIM# 144010), and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) [Abifadel et al., 2003] genes.”
BackgroundSelf-citationThe pharmacological management of metabolic syndrome
Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 113
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 131
Grošelj, U., Kovač, J., Šuštar, U., Mlinarič, M., Fras, Z., Podkrajšek, K. T., & Battelino, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.858 · Cited by 131
Mechanisms of Mendelian dominance
Veitia, R. A., Caburet, S., & Birchler, J. A. (2018) · Clinical Genetics · doi:10.1111/cge.13107 · Cited by 104
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 129
Lipid lowering therapy and circulating PCSK9 concentration
Nozue, T. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17012 · Cited by 127
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Abifadel, M., Guérin, M., Benjannet, S., Rabès, J., Goff, W. L., Julia, Z., Hamelin, J., Carreau, V., Varret, M., Bruckert, É., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.006 · Cited by 127
Self-citationTibolla, G., Norata, G. D., Artali, R., Meneghetti, F., & Catapano, A. L. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.06.002 · Cited by 127
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 126
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xia, X.-D., Peng, Z.-S., Gu, H.-M., Wang, M., Wang, G.-Q., & Zhang, D.-W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.764038 · Cited by 125
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 127
Browning, J. D., & Horton, J. D. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p009860 · Cited by 105
Tai, M., Chen, P., Chen, P., Wu, M., Ho, C., & Yen, J. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400366 · Cited by 124
PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
Langhi, C., May, C. L., Gmyr, V., Vandewalle, B., Kerr-Conte, J. A., Krempf, M., Pattou, F. N., Costet, P., & Cariou, B. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.138 · Cited by 124
Self-citationMolecular characterization of familial hypercholesterolemia in Spain
Palacios, L., Grandoso, L., Cuevas, N., Olano-Martin, E., Martinez, A., Tejedor, D., & Stef, M. A. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.021 · Cited by 124
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
Shapiro, M. D., & Fazio, S. (2017) · F1000Research · doi:10.12688/f1000research.9845.1 · Cited by 97
Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 123
Pisciotta, L., Oliva, C. P., Cefalù, A. B., Noto, D., Bellocchio, A., Fresa, R., Cantafora, A., Patel, D., Averna, M., Tarugi, P., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.015 · Cited by 108
APOE p.Leu167del mutation in familial hypercholesterolemia
Awan, Z. A., Choi, H. Y., Stitziel, N. O., Ruel, I. L., Bamimore, M. A., Husa, R., Gagnon, M.-H., Wang, R.-H. L., Peloso, G. M., Hegele, R. A., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.007 · Cited by 123
Self-citationInfluence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
Ghosh, M., Gälman, C., Rudling, M., & Angelin, B. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m055780 · Cited by 115
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
Mousavi, S. A., Berge, K. E., & Leren, T. P. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02167.x · Cited by 112
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Poirier, S., Prat, A., Marcinkiewicz, E., Paquin, J., Chitramuthu, B. P., Baranowski, D., Cadieux, B., Bennett, H. P. J., & Seidah, N. G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03928.x · Cited by 121
Self-citationSmall Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
German, C. A., & Shapiro, M. D. (2019) · BioDrugs · doi:10.1007/s40259-019-00399-6 · Cited by 121
Lambert, G., Jarnoux, A.-L., Pineau, T., Pape, O., Chetiveaux, M., Laboisse, C., Krempf, M., & Costet, P. (2006) · Endocrinology · doi:10.1210/en.2006-0098 · Cited by 112
Self-citationHepatic Proprotein Convertases Modulate HDL Metabolism
Jin, W., Wang, X., Millar, J. S., Quertermous, T., Rothblat, G. H., Glick, J. M., & Rader, D. J. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.009 · Cited by 120
PCSK9 and cancer: Rethinking the link
Mahboobnia, K., Pirro, M., Marini, E., Grignani, F., Bezsonov, E. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111758 · Cited by 105
Schmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y., Lin, A., Kowala, M. C., Alborn, W. E., Konrad, R. J., & Cao, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.004 · Cited by 120
Genetics of Cardiovascular Diseases: From Single Mutations to the Whole Genome
Cambien, F., & Tiret, L. (2007) · Circulation · doi:10.1161/circulationaha.106.661751 · Cited by 120
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 101
RNAi-based therapeutic strategies for metabolic disease
Czech, M., Aouadi, M., & Tesz, G. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.57 · Cited by 118
Stitziel, N. O., Fouchier, S. W., Sjouke, B., Peloso, G. M., Moscoso, A. M., Auer, P. L., Goel, A., Gigante, B., Barnes, T. A., Melander, O., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302426 · Cited by 118
Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
Harada‐Shiba, M., Arai, H., Ohmura, H., Okazaki, H., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.cr005 · Cited by 118
ROS-Induced Endothelial Dysfunction in the Pathogenesis of Atherosclerosis
Yan, R., Zhang, X., Xu, W., Li, J., Sun, Y., Cui, S., Xu, R., Li, W., Jiao, L., & Wang, T. (2024) · Aging and Disease · doi:10.14336/ad.2024.0309 · Cited by 118
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
Seidah, N. G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041865 · Cited by 117
Self-citationSeidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Self-citationLu, H., Howatt, D. A., Balakrishnan, A., Graham, M. J., Mullick, A. E., & Daugherty, A. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307613 · Cited by 116
Genetic contributors toward increased risk for ischemic heart disease
Nordlie, M. A., Wold, L. E., & Kloner, R. A. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.06.006 · Cited by 116
Nour, N., Mayer, G., Mort, J. S., Salvas, A., Mbikay, M., Morrison, C. J., Overall, C. M., & Seidah, N. G. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-06-0504 · Cited by 94
Self-citationMolecular spectrum of autosomal dominant hypercholesterolemia in France
Marduel, M., Carrié, A., Sassolas, A., Devillers, M., Carreau, V., Di Filippo, M., Erlich, D., Abifadel, M., Marques-Pinheiro, A., Munnich, A., et al. (2010) · Human Mutation · doi:10.1002/humu.21348 · Cited by 115
“Subsequently, we identified a third ADH-causative gene: proprotein convertase subtilisin-kexin type 9 (PCSK9; MIM# 607787) (Abifadel et al. 2003).”
BackgroundSelf-citationPaquette, M., Chong, M., Thériault, S., Dufour, R., Paré, G., & Baass, A. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.03.019 · Cited by 115
Management of patients with familial hypercholesterolaemia
Reiner, Ž. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.92 · Cited by 115
Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly
Shelness, G. S., & Ledford, A. S. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000169353.12772.eb · Cited by 100
Ridker, P. M., Rifai, N., Bradwin, G., & Rose, L. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv568 · Cited by 111
Werner, C. M., Hoffmann, M. M., Winkler, K., Böhm, M., & Laufs, U. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.03.004 · Cited by 114
Kastelein, J. J. P., Robinson, J. G., Farnier, M., Krempf, M., Langslet, G., Lorenzato, C., Gipe, D. A., & Baccara-Dinet, M. T. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6523-z · Cited by 102
Self-citationCan LDL cholesterol be too low? Possible risks of extremely low levels
Olsson, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo‐Minguez, A., Cohen, J., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 100
The potential of induced pluripotent stem cell derived hepatocytes
Hannoun, Z., Steichen, C., Dianat, N., Weber, A., & Dubart‐Kupperschmitt, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.025 · Cited by 113
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 100
van der Graaf, A., Avis, H. J., Kusters, D. M., Vissers, M. N., Hutten, B. A., Defesche, J. C., Huijgen, R., Fouchier, S. W., Wijburg, F. A., Kastelein, J. J. P., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.979450 · Cited by 106
The proprotein convertases and their implication in sterol and/or lipid metabolism
Seidah, N. G., Khatib, A. M., & Prat, A. (2006) · Biological Chemistry · doi:10.1515/bc.2006.110 · Cited by 95
Self-citationMayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., & Chrétien, M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165191 · Cited by 111
Self-citationAbifadel, M., Elbitar, S., Khoury, P. E., Ghaleb, Y., Chemaly, M., Moussalli, M.-L., Rabès, J., Varret, M., & Boileau, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0439-8 · Cited by 111
Self-citationFunctional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus
Kessler, T., Wobst, J., Wolf, B., Eckhold, J., Vilne, B., Hollstein, R., von Ameln, S., Dang, T. A., Sager, H. B., Moritz Rumpf, P., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024152 · Cited by 101
Mono- and biallelic variant effects on disease at biobank scale
Heyne, H., Karjalainen, J. M., Karczewski, K. J., Lemmelä, S. M., Zhou, W., FinnGen, Havulinna, A. S., Kurki, M., Rehm, H. L., Palotie, A. V., et al. (2023) · Nature · doi:10.1038/s41586-022-05420-7 · Cited by 111
Alsters, S., Goldstone, A. P., Buxton, J. L., Zekavati, A., Sosinsky, A., Yiorkas, A. M., Holder, S., Klaber, R. E., Bridges, N., van Haelst, M. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131417 · Cited by 111
PCSK9 as a therapeutic target of dyslipidemia
Seidah, N. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802600715 · Cited by 110
Self-citationCariou, B., Langhi, C., Le Bras, M., Bortolotti, M., Lê, K.-A., Theytaz, F., Le May, C., Guyomarc’h-Delasalle, B., Zaïr, Y., Kreis, R., et al. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-4 · Cited by 110
Self-citationDiagnosing familial hypercholesterolaemia: the relevance of genetic testing
van Aalst-Cohen, E. S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl113 · Cited by 110
Lebeau, P. F., Byun, J. H., Platko, K., Saliba, P., Sguazzin, M., MacDonald, M. E., Paré, G., Steinberg, G. R., Janssen, L. J., Igdoura, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28240-9 · Cited by 110
Self-citationHalf a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Mabuchi, H. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16008 · Cited by 110
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
The genetics of familial combined hyperlipidaemia
Brouwers, M. C. G. J., van Greevenbroek, M. M. J., Stehouwer, C. D. A., de Graaf, J., & Stalenhoef, A. F. H. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.15 · Cited by 109
Ruscica, M., Ricci, C., Macchi, C., Magni, P., Cristofani, R., Liu, J., Corsini, A., & Ferri, N. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664706 · Cited by 109
Proprotein Convertase Subtilisin/Kexin Type 9
Macchi, C., Ferri, N., Sirtori, C. R., Corsini, A., Banach, M., & Ruscica, M. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2021.04.016 · Cited by 100
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221100107 · Cited by 96
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
Kourimate, S., Le May, C., Langhi, C., Jarnoux, A. L., Ouguerram, K., Zaïr, Y., Nguyen, P., Krempf, M., Cariou, B., & Costet, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705831200 · Cited by 95
Self-citationPCSK9: From discovery to therapeutic applications
Farnier, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.10.007 · Cited by 108
Self-citationZanoni, P., Velagapudi, S., Yalcinkaya, M., Rohrer, L., & von Eckardstein, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.881 · Cited by 95
Zhang, L., McCabe, T., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 101
Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113035 · Cited by 107
Rousselet, E., Marcinkiewicz, J., Kriz, J., Zhou, A., Hatten, M. E., Prat, A., & Seidah, N. G. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014118 · Cited by 107
Self-citationMark, H. (2017) · doi:10.1016/j.jacc.2017.10.001 · Cited by 107
Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Steinberg, D., & Witztum, J. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904560106 · Cited by 107
Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
Miao, J., Manthena, P. V., Haas, M. E., Ling, A. V., Shin, D.-J., Graham, M. J., Crooke, R. M., Liu, J., & Biddinger, S. B. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305688 · Cited by 93
Liu, A., & Frostegård, J. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12758 · Cited by 93
Pisciotta, L., Oliva, C. P., Pes, G. M., Di Scala, L., Bellocchio, A., Fresa, R., Cantafora, A., Arca, M., Calandra, S., & Bertolini, S. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.11.016 · Cited by 98
Oestrogen-modulated gene expression in the human endometrium
Punyadeera, C., Dassen, H. H. N. M., Klomp, J. P. G., Dunselman, G. A. J., Kamps, R., Dijcks, F. A., EDERVEEN, A. G. H., de Goeij, A. F. P. M., & Groothuis, P. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4435-y · Cited by 107
Petersen, D. N., Hawkins, J., Ruangsiriluk, W., Stevens, K. A., Maguire, B. A., O’Connell, T. N., Rocke, B. N., Boehm, M., Ruggeri, R. B., Rolph, T., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.08.016 · Cited by 107
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Stoekenbroek, R. M., Kallend, D., Wijngaard, P. L., & Kastelein, J. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0067 · Cited by 106
The PCSK9 revolution: Current status, controversies, and future directions
Warden, B. A., Fazio, S., & Shapiro, M. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.007 · Cited by 100
Current management of severe homozygous hypercholesterolaemias
Naoumova, R. P., Thompson, G. R., & Soutar, A. K. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137222.23784.2a · Cited by 96
Familial hypercholesterolaemia in Portugal
Bourbon, M., Alves, A. C., Medeiros, A. M., Silva, S. D. R., & Soutar, A. K. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.019 · Cited by 106
Scartezini, M., Hubbart, C., Whittall, R. A., Cooper, J. A., Neil, A. H. W., & Humphries, S. E. (2007) · Clinical Science · doi:10.1042/cs20070150 · Cited by 96
Selective gene silencing by viral delivery of short hairpin RNA
Sliva, K., & Schnierle, B. S. (2010) · Virology Journal · doi:10.1186/1743-422x-7-248 · Cited by 105
Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400396-jlr200 · Cited by 104
“Recently, Proprotein Convertase Subtilisin Kexin 9 (PCSK9) has been identified as the third gene involved in autosomal dominant hypercholesterolemia (5).”
BackgroundSelf-citationWang, Y., Huang, Y., Hobbs, H. H., & Cohen, J. C. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m028563 · Cited by 104
Jang, H.-D., Lee, S. E., Yang, J., Lee, H.-C., Shin, D., Lee, H., Lee, J., Jin, S., Kim, S., Lee, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz566 · Cited by 99
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 104
Taskinen, M.-R., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 90
Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity
Fan, D., Yancey, P. G., Qiu, S., Ding, L., Weeber, E. J., Linton, M. F., & Fazio, S. (2008) · Biochemistry · doi:10.1021/bi7016359 · Cited by 103
Lipari, M. T., Li, W., Moran, P., Kong-Beltran, M., Sai, T., Lai, J., Lin, S. J., Kolumam, G., Zavala-Solorio, J., Izrael-Tomasevic, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380618 · Cited by 92
Mayer, G., & Poirier, S. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s36984 · Cited by 84
Genome-wide association studies of cardiovascular disease
Walsh, R., Jurgens, S. J., Erdmann, J., & Bezzina, C. R. (2023) · Physiological Reviews · doi:10.1152/physrev.00024.2022 · Cited by 102
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.